Provided by Tiger Trade Technology Pte. Ltd.

Sequoia Capital Holdings

3,347.77
-8.2666-0.25%
Number of Gainers:37
Number of Losers:61
Number of Flat:2
PE:- -
High:3,355.82
Open:3,355.82
Low:3,320.93
Close:3,355.84
Volume:233.45M
Turnover:54.25B
Market Cap:44.02T
Float Cap:41.14T

Loading ...

Moderna Stock Surges 70%, Merck Rises 6%. at Last, a Successful Cancer Vaccine.

Dow Jones
·
Aug 19

AI Spending Just Revealed a $7,000 Gap Between Winners and Losers

InvestorPlace
·
Aug 19

META, MSFT and AMZN Face Rising Costs and Delays as AI Data Center Backlash Grows

TIPRANKS
·
Aug 19

Moderna and Merck Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Moderna Vaccine Cuts Recurrence and Spread of High-Risk Melanoma, Raising New Treatment Hope

Reuters
·
Aug 19

Unified Communications Platform Helps Businesses Simplify Communications Across Sparklight Service Areas

GlobeNewswire
·
Aug 19

Goldman Sachs Remains a Hold on Natura Cosmeticos SA (NATU3)

TIPRANKS
·
Aug 19

Magazine Luiza S.A. (MGLU3) Receives a Hold from Goldman Sachs

TIPRANKS
·
Aug 19

HFT Fund Reports Doubled First-Half Revenue and Profit, With Both Metrics Surging Around 98% Year-On-Year

Deep News
·
Aug 19

Google Parent Taps Australian Bond Market for First Time, Raising $3.9 Billion Amid Global Tech Debt Rush

Stock News
·
Aug 19

Merck Shares Rise 1.9% Premarket

THOMSON REUTERS
·
Aug 19

AI and Robotics are a Battleground for U.S. and China. This is the Best Bet.

Dow Jones
·
Aug 19

Alphabet Raises $3.9 Billion in Inaugural Australian Dollar Bond

Reuters
·
Aug 19

Merck, Moderna Say Melanoma Skin Cancer Vaccine Meets Goals in Large Trial

Reuters
·
Aug 19

Merck: Safety Profiles of Intismeran and Keytruda in Trial were Consistent with Prior Reported Studies for the Combination

THOMSON REUTERS
·
Aug 19

Merck: Phase 3 Interpath-001 Trial of Intismeran Autogene Plus Keytruda Met Primary Endpoint of Recurrence Free Survival

THOMSON REUTERS
·
Aug 19

Merck: Co, Moderna Announce Positive Results from Phase 3 Interpath-001 Trial for Patients with Completely Resected Stage Iib-Iv Melanoma

THOMSON REUTERS
·
Aug 19

Musk Robot Rival Soars 460% in China Stock Market Debut

Dow Jones
·
Aug 19

Merck: Co, Moderna Will Engage with Regulators on Filing Submissions for Intismeran Autogene in Combination with Keytruda

THOMSON REUTERS
·
Aug 19

Microsoft’s AI CMO Mallard to leave company, Business Insider reports

TIPRANKS
·
Aug 19